Twinject is a drug owned by Impax Laboratories Llc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 04, 2025. Details of Twinject's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7621891 | Method and apparatus for delivering epinephrine |
Feb, 2025
(1 year, 7 months ago) |
Expired
|
| US7297136 | Medicine injection devices and methods |
Jan, 2025
(1 year, 8 months ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Twinject's patents.
Latest Legal Activities on Twinject's Patents
Given below is the list of recent legal activities going on the following patents of Twinject.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Dec, 2020 | US7621891 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 May, 2019 | US7297136 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 31 May, 2011 | US7297136 |
| Change in Power of Attorney (May Include Associate POA) | 20 Apr, 2010 | US7621891 |
| Change in Power of Attorney (May Include Associate POA) | 20 Apr, 2010 | US7297136 |
| Correspondence Address Change | 16 Apr, 2010 | US7297136 |
| Correspondence Address Change | 16 Apr, 2010 | US7621891 |
| Patent Issue Date Used in PTA Calculation | 24 Nov, 2009 | US7621891 |
| Recordation of Patent Grant Mailed | 24 Nov, 2009 | US7621891 |
| Issue Notification Mailed | 04 Nov, 2009 | US7621891 |
US patents provide insights into the exclusivity only within the United States, but
Twinject is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Twinject's family patents as well as insights into
ongoing legal events
on those patents.
Twinject's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Twinject:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
Generic Launch
Generic Release Date:
Twinject's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 04, 2025 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Twinject Generic API suppliers:
Epinephrine is the generic name for the brand Twinject. 9 different companies have already filed for the generic of Twinject, with Gland having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Twinject's generic
Alternative Brands for Twinject
There are several other brand drugs using the same active ingredient (Epinephrine) as Twinject. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Adamis Pharms Corp |
| ||
| Armstrong Pharms |
| ||
| Ars Pharms Operation |
| ||
| Baxter Hlthcare Corp |
| ||
| Bpi Labs |
| ||
| Fresenius Kabi Usa |
| ||
| Impax |
| ||
| Inforlife |
| ||
| Kaleo Inc |
| ||
| Long Grove Pharms |
| ||
| Ph Health |
| ||
| Viatris |
| ||
| Vyteris |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Epinephrine, Twinject's active ingredient. Check the complete list of approved generic manufacturers for Twinject
About Twinject
Twinject is a drug owned by Impax Laboratories Llc. Twinject uses Epinephrine as an active ingredient. Twinject was launched by Impax in 2009.
Approval Date:
Twinject was approved by FDA for market use on 25 November, 2009.
Active Ingredient:
Twinject uses Epinephrine as the active ingredient. Check out other Drugs and Companies using Epinephrine ingredient
Dosage:
Twinject is available in injectable form for intramuscular, subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 0.3MG/DELIVERY | INJECTABLE | Discontinued | INTRAMUSCULAR, SUBCUTANEOUS |
| EQ 0.15MG/DELIVERY | INJECTABLE | Discontinued | INTRAMUSCULAR, SUBCUTANEOUS |